Caligan Partners’s Inhibrx INBX Stock Holding History

Caligan Partners’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150,000	Closed	-$11.8M	–	30
2025 Q4	$11.8M	Buy	+150,000	New	+$10.2M	0.98%	18

Other funds holding INBX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Caligan Partners's INBX Position: Q1 2026 in Review

Caligan Partners sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 323,565 shares — an estimated $25.6M sold.

Caligan Partners first reported a position in INBX in Q3 2025 and held it in 2 quarters. The position peaked at $25.6M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

Caligan Partners reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
Caligan Partners sold 323,565 Inhibrx shares in Q1 2026, an estimated $25.6M.
Caligan Partners first reported a position in Inhibrx in Q3 2025 and held it in 2 quarters.
Caligan Partners's Inhibrx position peaked at $25.6M in Q4 2025.
135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.